Table 1. Individual SGLT2 inhibitor pharmacokinetics.

SGLT2 - sodium-glucose cotransporter-2; eGFR - estimated glomerular filtration rate

Drug	Half-life (t1/2)	Time to peak action	Plasma protein binding	Bioavailability	Contra-indication
Canagliflozin	11-13 hr	1-2 hr	99%	~65%	eGFR<30 ml/min/1.73m2
Dapagliflozin	~13 hr	1-1.5 hr	78%	~78%	eGFR <60 ml/min/1.73m2
Empagliflozin	~13 hr	1.5 hr	86%	~75%	eGFR <45 ml/min/1.73m2
Ertugliflozin	11-17 hr	0.5-1.5 hr	-	70-90%	eGFR<30 ml/min/1.73m2
Ipragliflozin	15-16 hr	1.5 hr	-	~90%	(Only approved in Japan)
Tofogliflozin	5-6 hr	0.5-1.5 hr	-	~97.5%	(Only approved in Japan)